Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term safety of GSK2402968 in Duchenne muscular dystrophy
2011-001266-17Phase 3Terminated
- Sponsor
- GSK
- Start
- Jun 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of drisapersen in Duchenne muscular dystrophy (DMD), sponsored by GSK. Primary endpoints: Long-term safety of GSK2402968 and Long-term efficacy of GSK2402968. Started Jun 2011; status: terminated.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2011-001266-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001266-17.